Brief: Annovis Announces Novel Biomarker Data In Alzheimer’S Patients Supporting Buntanetap’S Potential As A Disease-Modifying Treatment
09/10/2025 12:35
Oct 9 (Reuters) - Annovis Bio Inc ANVS.N: ANNOVIS ANNOUNCES NOVEL BIOMARKER DATA IN ALZHEIMER’S PATIENTS SUPPORTING BUNTANETAP’S POTENTIAL AS A DISEASE-MODIFYING TREATMENT ANNOVIS BIO INC - BUNTANETAP IN PHASE 3 TRIAL FOR EARLY ALZHEIMER'S Source text: ID:nGNX2nSQxF Further company coverage: ANVS.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Annovis Bio
See all newsAnnovis Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Annovis Bio Q2 loss widens as R&D costs rise
Annovis Bio Inc expected to post a loss of 45 cents a share - Earnings Preview
Brief: Annovis Announces Pricing Of $15.0 Million Public Offering Of Common Stock And Accompanying Warrants
U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman